Similar Efficacy Seen in 2 Newer Antibiotics
A multicenter observational study that compared the effectiveness of ceftazidime-avibactam (CZA) with ceftolozane-tazobactam (C/T) for multidrug-resistant (MDR) Pseudomonas aeruginosa infections showed no difference in overall clinical success, mortality, recurrent infections or resistance development (poster 1109).
The study, known as CACTUS, focused on the real-world effectiveness of antimicrobial agents against MDR pathogens.